Relistor, produced by Tarrytown, N.Y.-based Progenics Pharmaceuticals, was originally approved in 2008 as an injectable.
Protogenics sold the licensing rights of Relistor to Raleigh, N.C.-based Salix Pharmaceuticals in 2011, which was later acquired by Canada-based Valeant for $11.1 billion in 2015.
Valeant agreed to give Progenics a $50 million milestone payment pending the FDA approval.
Valeant and Progenics hope to launch Relistor in the third quarter of 2016.
More articles on the drug market:
India’s growing role in the US generic drug market: 5 things to know
Patients expect discounts for soaring drug costs: 3 things to know
Brexit’s threat to the drug industry doesn’t scare Novartis
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
